Literature DB >> 2208011

Clinical prognostic factors in patients with posterior uveal malignant melanoma.

J J Augsburger1, J W Gamel.   

Abstract

The authors evaluated the prognostic value of clinically assessed variables for predicting length of survival until death from metastatic disease in 237 patient with a primary choroidal or ciliary body melanoma. Using multivariate Cox proportional hazards modeling, the authors identified the largest linear basal tumor diameter (mm), estimated by indirect ophthalmoscopy and fundus drawing, the location of the anterior margin of the tumor relative to the ocular equator and ora serrata, and the age of the patient at the time of treatment as the best combination of the clinically assessed variables for predicting survival. For each patient in this group, the authors computed a prognostic index based on the best multivariate Cox model. They showed that patients with low, intermediate, and high values of prognostic index had low, intermediate, and high melanoma-related mortality rates, respectively, during the first 5 to 8 posttreatment years. These results suggest that: (1) clinically assessed variables evaluated according to a standardized protocol are useful for predicting the survival of treated patients with posterior uveal melanoma and (2) ophthalmologists who assess potential clinical prognostic variables consistently may identify subgroups of patients with comparable mortality risk on the basis of noninvasive testing.

Entities:  

Mesh:

Year:  1990        PMID: 2208011     DOI: 10.1002/1097-0142(19901001)66:7<1596::aid-cncr2820660726>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

Review 1.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

2.  DNA ploidy pattern in choroidal melanoma: correlation with survival. A flow cytometry study on archival material.

Authors:  P Toti; G Greco; P Mangiavacchi; A Bruni; M L Palmeri; P Luzi
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

Review 3.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

4.  Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.

Authors:  Cindy Weidmann; Julie Bérubé; Léo Piquet; Arnaud de la Fouchardière; Solange Landreville
Journal:  Clin Exp Metastasis       Date:  2018-04-25       Impact factor: 5.150

5.  Clinical Features, Metastasis, and Survival in Patients Younger Than 21 Years With Posterior Uveal Melanoma.

Authors:  Matthew V Fry; James J Augsburger; Zélia M Corrêa
Journal:  JAMA Ophthalmol       Date:  2019-01-01       Impact factor: 7.389

Review 6.  Emerging insights into the molecular pathogenesis of uveal melanoma.

Authors:  Solange Landreville; Olga A Agapova; J William Harbour
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

7.  Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma.

Authors:  Scott D Walter; Daniel L Chao; William Feuer; Joyce Schiffman; Devron H Char; J William Harbour
Journal:  JAMA Ophthalmol       Date:  2016-07-01       Impact factor: 7.389

Review 8.  Is observation really appropriate for small choroidal melanomas.

Authors:  J J Augsburger
Journal:  Trans Am Ophthalmol Soc       Date:  1993

Review 9.  An alternative hypothesis for observed mortality rates due to metastasis after treatment of choroidal melanomas of different sizes.

Authors:  James J Augsburger; Zélia M Corrêa; Nikolaos Trichopoulos
Journal:  Trans Am Ophthalmol Soc       Date:  2007

10.  [Acute angle closure glaucoma with unilateral acute loss of vision].

Authors:  R Khaireddin; G Richard; S J Linke
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.